SNSP113 is an inhaled glycopolymer, a type of molecule being developed to treat infection and inflammation in the lungs. When bacteria infect the lungs of people with CF, it can form structures called biofilms. Biofilms make bacteria more resistant to antibiotics. SNSP113 helps break up biofilms in the lungs, allowing antibiotics to fight bacteria more effectively. SNSP113 may also make mucus thinner and less sticky, reducing inflammation and improving airway clearance. 

Status

A phase 1 study to test the safety of SNSP113 in healthy adults was completed. No further studies in CF are planned at this time.

Sponsor

This program was sponsored by Synspira and partially funded by the Cystic Fibrosis Foundation.